Clinical Trial Update: Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating erlotinib (Tarceva) as a single agent or intercalated with chemotherapy in EGFR-positive non-small cell lung cancer; the trial is compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: OSI Pharmaceuticals | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2011-02-14